false
OasisLMS
Catalog
SCCM Resource Library
Hitting More Than the Target: Toxicities of Immune ...
Hitting More Than the Target: Toxicities of Immune Checkpoint Inhibitors and Other Targeted Therapies for Cancer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The presentation focused on the toxicities associated with immune checkpoint inhibitors, immune effector cell therapy, monoclonal antibodies, and CAR T-cell therapies in cancer treatment. These therapies revolutionize cancer care by enhancing immune responses against cancer cells but can cause severe side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is a hyperinflammatory response common in CAR T-cell therapy, potentially landing patients in ICU due to severe symptoms. ICANS, another side effect, can vary from mild symptoms to life-threatening conditions like cerebral edema. Management involves steroids and tocilizumab, targeting cytokine pathways. Monoclonal antibodies can cause hypersensitivity and organ-specific toxicities. Immune checkpoint inhibitors, effective in solid organ malignancies, can induce a range of immune-related adverse effects affecting multiple body systems. Early recognition and collaboration with oncologists are crucial for managing these toxicities while minimizing disruptions to lifesaving cancer treatments.
Asset Caption
One-Hour Concurrent Session | New Drug, Who's Toxic? New and Emerging Drug Toxicities
Meta Tag
Content Type
Presentation
Membership Level
Professional
Membership Level
Select
Year
2024
Keywords
immune checkpoint inhibitors
CAR T-cell therapy
cytokine release syndrome
immune effector cell-associated neurotoxicity
monoclonal antibodies
×
Please select your language
1
English